Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

A New Solution for the Multibillion-Dollar Bladder Cancer Problem

Stockhouse Editorial
0 Comments| May 25, 2020

{{labelSign}}  Favorites
{{errorMessage}}

Bladder cancer is the sixth-most prevalent cancer in North America and has a recurrence rate greater than 50%, making it Click to enlargethe most expensive cancer to treat. All-in costs in the US are around $4 billion and roughly 80,000 new American cases are reported each year, with 350,000 cases internationally.

Targeting bladder cancer is Imagin Medical Inc. (CSE: IME, OTCQB: IMEXF, Forum), a bio-medical research and development Company developing a new method to visualize cancer through minimally invasive surgery that could drastically improve the means by which physicians can visualize the surgical field and detect cancer The company’s initial target is bladder cancer.

Click to enlargeThe Company’s i/Blue Imaging System uses proprietary optics and light sensors to combine blue and white light with an FDA-approved drug to significantly increase the efficiency and accuracy of detecting cancer.

We are joined by Imagin’s Chief Executive Officer, Jim Hutchens to learn more about this Company’s work ....



Download the episode here.




Listen on Apple PodcastsListen on Google Podcasts


FULL DISCLOSURE: Imagin Medical Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today